Parker, H.
Carr, L.
Norris, K. https://orcid.org/0000-0002-6448-8696
Nilsson-Takeuchi, A.
Stevens, B.
Amarasinghe, H.
Kadalayil, L.
Else, M. https://orcid.org/0000-0001-8578-4796
Clifford, R.
Pettitt, A.
Munir, T.
Schuh, A. https://orcid.org/0000-0002-3938-8490
Walewska, R.
Baird, D. M. https://orcid.org/0000-0001-8408-5467
Oscier, D. G.
Pepper, C.
Bryant, D. https://orcid.org/0000-0003-3163-608X
Gibson, J. https://orcid.org/0000-0002-0973-8285
Strefford, JC https://orcid.org/0000-0002-0972-2881
Funding for this research was provided by:
Kay Kendall Leukaemia Fund (873)
Cancer Research UK (C42023/A29370)
Cancer Research UK (C17199/A29202)
Department of Health | National Health and Medical Research Council
Article History
Received: 13 October 2025
Revised: 27 January 2026
Accepted: 24 February 2026
First Online: 11 March 2026
Competing interests
: DMB, KN and CP are founding shareholders of TeloNostiX Ltd.